SGLT2抑制剂与二甲双胍预防2型糖尿病谵妄的比较:一项真实世界头对头比较研究
基于TriNetX全球健康研究网络的回顾性队列研究,纳入2005至2025年857,171例启动SGLT2抑制剂(n=88,012)或二甲双胍(n=769,159)的2型糖尿病成人,经倾向评分1:1匹配后,SGLT2抑制剂组谵妄风险显著低于二甲双胍组(ARR 5.03%,3.97% vs. 9.0%;aHR 0.91 [95% CI 0.87, 0.95],P < 0.001),全因死亡率亦更低(ARR 9.23%,aHR 0.85 [95% CI 0.87, 0.88],P < 0.001)。
要点
- 匹配后SGLT2抑制剂组谵妄风险显著低于二甲双胍组(aHR 0.91,95% CI 0.87, 0.95,P < 0.001)。
- SGLT2抑制剂组全因死亡率亦更低(aHR 0.85,95% CI 0.87, 0.88,P < 0.001)。
- ≥80岁成人(aHR 0.83,P < 0.0001)、男性及使用胰岛素或镇静剂的高危亚组获益最明显。
核心结论
- 这项首个头对头真实世界研究提示,在2型糖尿病患者中SGLT2抑制剂较二甲双胍可能提供更优的谵妄保护,尤其在高危人群。
- 作者认为这些发现支持将认知结局纳入糖尿病治疗决策,并提示一线治疗策略可能存在潜在转变。
研究设计与样本
- 采用TriNetX全球健康研究网络的回顾性队列研究,纳入2005至2025年857,171例2型糖尿病成人,其中启动SGLT2抑制剂者88,012例、启动二甲双胍者769,159例。
- 使用倾向评分匹配(1:1)平衡组间协变量,主要结局为谵妄发生,次要结局包括全因死亡率。
主要发现
- 匹配后SGLT2抑制剂组谵妄风险显著低于二甲双胍组(ARR 5.03%,3.97% vs. 9.0%;aHR 0.91 [95% CI 0.87, 0.95],P < 0.001)。
- SGLT2抑制剂组全因死亡率亦低于二甲双胍组(ARR 9.23%,aHR 0.85 [95% CI 0.87, 0.88],P < 0.001)。
- ≥80岁成人(aHR 0.83,P < 0.0001)、男性以及使用胰岛素或镇静剂的高危亚组获益最明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2is) versus metformin in preventing delirium among patients with type 2 diabetes (T2D), using real-world data. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study using the TriNetX global health research network, including 857,171 adults with T2D who initiated either an SGLT2i (n = 88,012) or metformin (n = 769,159) from 2005 to 2025. Propensity score matching (1:1) was used to balance covariates between groups. The primary outcome was incident delirium; secondary outcomes included all-cause mortality. Absolute risk reduction (ARR), adjusted hazard ratios (aHRs), and Kaplan-Meier survival analyses were used to assess outcomes. RESULTS: After matching, SGLT2i use was associated with a significantly lower risk of delirium compared with metformin (ARR 5.03%, 3.97% vs. 9.0%; aHR 0.91 [95% CI 0.87, 0.95], P < 0.001). All-cause mortality was also lower in the SGLT2i group (ARR 9.23%, aHR 0.85 [95% CI 0.87, 0.88], P < 0.001). The most pronounced benefits were seen in adults aged ≥80 years (aHR 0.83, P < 0.0001), males, and high-risk subgroups using insulin or sedatives. CONCLUSIONS: This first head-to-head, real-world study suggests that SGLT2is may offer superior protection against delirium compared with metformin in patients with T2D, especially in high-risk populations. These findings support the inclusion of cognitive outcomes in diabetes treatment decisions and suggest a potential shift in first-line therapy strategies.
引用
- Sun M, Wang X, Lu Z, et al. SGLT2is Versus Metformin for Delirium Prevention in Type 2 Diabetes: A Real-World, Head- to-Head Comparative Study. Diabetes Care. 2025. PMID: 40435363. doi:10.2337/dc25-0433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。